Surmontil (trimipramine) is a small molecule pharmaceutical. Trimipramine was first approved as Surmontil on 1982-01-01. It is used to treat depressive disorder and psychotic affective disorders in the USA. The pharmaceutical is active against sodium-dependent dopamine transporter, sodium-dependent serotonin transporter, and sodium-dependent noradrenaline transporter. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, muscarinic acetylcholine receptor M2, potassium voltage-gated channel subfamily H member 1, and G protein-activated inward rectifier potassium channel 4.
|Indication||depressive disorder, psychotic affective disorders|
|Drug Class||Antidepressants (imipramine type)|